BioCentury | Oct 1, 2019
Company News

Management tracks: Vertex taps Bozic as CMO; plus Nektar, Sangamo, Ascletis, Neurocrine, Neovacs, Dyne, Avidity, Pulmotect, Adaptimmune and 4BIO

...Sieler resigned. Serra joined Neovacs as CSO at the beginning of the year. Prior to Neovacs...
...and Match Next-Gen Therapies with $150M Fund” ). BioCentury Staff Vertex Pharmaceuticals Inc. Nektar Therapeutics Sangamo Therapeutics Inc. Neurocrine Biosciences Inc. Neovacs S.A. Ascletis...
BioCentury | Jun 18, 2019
Finance

Imcyse to test cell killing approach in autoimmune disease with €35M in new funding

...Vandepapelière. An 18-year veteran of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Vandepapelière was VP and CMO of Neovacs S.A....
BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

...Phase II results from its IFNα Kinoid vaccine, which induces polyclonal antibodies against the cytokine, Neovacs S.A....
...lupus studies that read out in 2018 failed to meet at least one primary endpoint. Neovacs S.A....
...feeling that the disease will overwhelm them again.” Miguel Sieler, Neovacs To overcome both hurdles, Neovacs...
BioCentury | Oct 5, 2018
Company News

BioSense exercises option for Chinese rights to Neovacs's IFNalpha Kinoid to treat lupus

...exclusive rights from Neovacs S.A. (Euronext:ALNEV) to develop and commercialize IFNalpha-Kinoid to treat lupus, in China. Neovacs...
...Dang Pharmaceutical Corp. (KSE:001630) has rights (see "Neovacs, Chong Kun Dang Deal" ). In July, Neovacs...
...Neovacs S.A. (Euronext:ALNEV), Paris, France BioSense Global LLC, East Rutherford, N.J. Business: Autoimmune Shannon Lehnbeuter IFNalpha-Kinoid (IFN-K, Antiferon) BioSense Global Neovacs S.A....
BioCentury | Sep 7, 2018
Clinical News

AZ's anifrolumab misses in Phase III for lupus

...tremendous heterogeneity and the unpredictable course of disease (see "On SLE's Trail" ). In July, Neovacs S.A....
...a Phase IIb trial in the indication. The candidate is an immunotherapy against IFNα (see "Neovacs...
BioCentury | Aug 31, 2018
Clinical News

AZ's anifrolumab misses in Phase III for lupus

...tremendous heterogeneity and the unpredictable course of disease (see "On SLE's Trail" ). In July, Neovacs S.A....
...a Phase IIb trial in the indication. The candidate is an immunotherapy against IFNα (see "Neovacs...
BioCentury | Jul 6, 2018
Clinical News

Neovacs planning Phase III for lupus therapy on mixed Phase IIb data

...Disease Activity Score (LLDAS) response rate at week 36 vs. placebo (52.9% vs. 29.8%, p=0.002). Neovacs...
...BILAG A and B domain scores. Benlysta is a human mAb against BLyS (BAFF; TNFSF13B). Neovacs'...
...presentation at a scientific meeting. IFNalpha-Kinoid has Fast Track designation in the U.S. for lupus. Neovacs S.A....
BioCentury | Jul 3, 2018
Clinical News

Neovacs planning Phase III for lupus therapy on mixed Phase IIb data

...Disease Activity Score (LLDAS) response rate at week 36 vs. placebo (52.9% vs. 29.8%, p=0.002). Neovacs...
...BILAG A and B domain scores. Benlysta is a human mAb against BLyS (BAFF; TNFSF13B). Neovacs'...
...in the U.S. for lupus. Neovacs was off €0.01 to €0.36 on Tuesday. Brian Moy IFNalpha-Kinoid (IFN-K, Antiferon) Neovacs S.A. Interferon...
BioCentury | Feb 13, 2018
Distillery Therapeutics

Cancer

...mAb against IL-4 and IL-13, in Phase II testing to treat scleroderma and pulmonary fibrosis. Neovacs S.A....
BioCentury | Jul 14, 2017
Clinical News

Third DSMB recommendation for Neovacs' Phase IIb of IFNalpha-Kinoid for SLE

...of the Phase IIb IFN-K-002 trial evaluating intramuscular IFNalpha-Kinoid (IFN-K) for systemic lupus erythematosus (SLE). Neovacs...
...Neovacs expects to report data in 2Q18. IFNalpha-Kinoid is an immunotherapy against interferon (IFN) alpha. Neovacs S.A....
...Index (SRI)-4 response criteria and safety Status: Phase IIb ongoing Milestone: Phase IIb data (2Q18) Meghan Sullivan IFN-K IFNalpha-Kinoid Neovacs S.A. Interferon...
Items per page:
1 - 10 of 101
BioCentury | Oct 1, 2019
Company News

Management tracks: Vertex taps Bozic as CMO; plus Nektar, Sangamo, Ascletis, Neurocrine, Neovacs, Dyne, Avidity, Pulmotect, Adaptimmune and 4BIO

...Sieler resigned. Serra joined Neovacs as CSO at the beginning of the year. Prior to Neovacs...
...and Match Next-Gen Therapies with $150M Fund” ). BioCentury Staff Vertex Pharmaceuticals Inc. Nektar Therapeutics Sangamo Therapeutics Inc. Neurocrine Biosciences Inc. Neovacs S.A. Ascletis...
BioCentury | Jun 18, 2019
Finance

Imcyse to test cell killing approach in autoimmune disease with €35M in new funding

...Vandepapelière. An 18-year veteran of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Vandepapelière was VP and CMO of Neovacs S.A....
BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

...Phase II results from its IFNα Kinoid vaccine, which induces polyclonal antibodies against the cytokine, Neovacs S.A....
...lupus studies that read out in 2018 failed to meet at least one primary endpoint. Neovacs S.A....
...feeling that the disease will overwhelm them again.” Miguel Sieler, Neovacs To overcome both hurdles, Neovacs...
BioCentury | Oct 5, 2018
Company News

BioSense exercises option for Chinese rights to Neovacs's IFNalpha Kinoid to treat lupus

...exclusive rights from Neovacs S.A. (Euronext:ALNEV) to develop and commercialize IFNalpha-Kinoid to treat lupus, in China. Neovacs...
...Dang Pharmaceutical Corp. (KSE:001630) has rights (see "Neovacs, Chong Kun Dang Deal" ). In July, Neovacs...
...Neovacs S.A. (Euronext:ALNEV), Paris, France BioSense Global LLC, East Rutherford, N.J. Business: Autoimmune Shannon Lehnbeuter IFNalpha-Kinoid (IFN-K, Antiferon) BioSense Global Neovacs S.A....
BioCentury | Sep 7, 2018
Clinical News

AZ's anifrolumab misses in Phase III for lupus

...tremendous heterogeneity and the unpredictable course of disease (see "On SLE's Trail" ). In July, Neovacs S.A....
...a Phase IIb trial in the indication. The candidate is an immunotherapy against IFNα (see "Neovacs...
BioCentury | Aug 31, 2018
Clinical News

AZ's anifrolumab misses in Phase III for lupus

...tremendous heterogeneity and the unpredictable course of disease (see "On SLE's Trail" ). In July, Neovacs S.A....
...a Phase IIb trial in the indication. The candidate is an immunotherapy against IFNα (see "Neovacs...
BioCentury | Jul 6, 2018
Clinical News

Neovacs planning Phase III for lupus therapy on mixed Phase IIb data

...Disease Activity Score (LLDAS) response rate at week 36 vs. placebo (52.9% vs. 29.8%, p=0.002). Neovacs...
...BILAG A and B domain scores. Benlysta is a human mAb against BLyS (BAFF; TNFSF13B). Neovacs'...
...presentation at a scientific meeting. IFNalpha-Kinoid has Fast Track designation in the U.S. for lupus. Neovacs S.A....
BioCentury | Jul 3, 2018
Clinical News

Neovacs planning Phase III for lupus therapy on mixed Phase IIb data

...Disease Activity Score (LLDAS) response rate at week 36 vs. placebo (52.9% vs. 29.8%, p=0.002). Neovacs...
...BILAG A and B domain scores. Benlysta is a human mAb against BLyS (BAFF; TNFSF13B). Neovacs'...
...in the U.S. for lupus. Neovacs was off €0.01 to €0.36 on Tuesday. Brian Moy IFNalpha-Kinoid (IFN-K, Antiferon) Neovacs S.A. Interferon...
BioCentury | Feb 13, 2018
Distillery Therapeutics

Cancer

...mAb against IL-4 and IL-13, in Phase II testing to treat scleroderma and pulmonary fibrosis. Neovacs S.A....
BioCentury | Jul 14, 2017
Clinical News

Third DSMB recommendation for Neovacs' Phase IIb of IFNalpha-Kinoid for SLE

...of the Phase IIb IFN-K-002 trial evaluating intramuscular IFNalpha-Kinoid (IFN-K) for systemic lupus erythematosus (SLE). Neovacs...
...Neovacs expects to report data in 2Q18. IFNalpha-Kinoid is an immunotherapy against interferon (IFN) alpha. Neovacs S.A....
...Index (SRI)-4 response criteria and safety Status: Phase IIb ongoing Milestone: Phase IIb data (2Q18) Meghan Sullivan IFN-K IFNalpha-Kinoid Neovacs S.A. Interferon...
Items per page:
1 - 10 of 101